Trial reportJCI insight2020
Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART.
Trial report in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 93 citations in OpenAlex.
- Long-term effect of temporary ART initiated during primary HIV-1 infection on viral persistence.Nature communications · 2025Trial
- Tissue origins and immune correlates of viral rebound in SIV-infected rhesus macaques after ART discontinuation.Science translational medicine · 2026Article
- DAMPs, PAMPs, and Alarmins: From Mechanism to Therapy.MedComm · 2026Review
- Early intervention, lasting impact: benefits of early antiretroviral therapy and implications for posttreatment control.Current opinion in HIV and AIDS · 2026Review
- Metabolic reprogramming of CD4⁺ T cells by Zaprinast induces HIV-1 latency reversal ex vivo.Retrovirology · 2026Article
- Article
- Early immune responses anticipate HIV rebound and precede viral control.bioRxiv : the preprint server for biology · 2026Article
- HIV-seq reveals gene expression differences between HIV-transcribing cells from viremic and suppressed people with HIV.Nature communications · 2026Article
- HIV-1 and HIV-2 interaction results in reduced cell infectivity and viral replication in vitro.Virology journal · 2026Article
- Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial.Nature communications · 2026Article
- Combining spironolactone to antiretroviral therapy accelerates HIV decay in humanized mice.Emerging microbes & infections · 2025Article
- Persistent cell-associated HIV-1 RNA in virally suppressed individuals on INSTI-based ART.Journal of virus eradication · 2025Article
- Identifying correlates of viral rebound timing and viral control in SHIV-infected infant macaques after ART interruption.Science translational medicine · 2025Article
- Longitudinal metabolomic profiling unveils dynamic biomarkers for predicting immune recovery in HIV-1 infection.Clinical and translational medicine · 2025Article
- Origin and Correlates of Viral Rebound in SIV-Infected Rhesus Macaques Following ART Discontinuation.bioRxiv : the preprint server for biology · 2025Article
- Differential decreases in various HIV DNA regions and HIV transcripts after ART initiation during chronic infection.Journal of virology · 2025Article
- Higher levels of cell-associated HIV-1 RNA transcripts predict risk of viral blips: implications for clinical management and cure research.AIDS (London, England) · 2025Article
- Improved HIV-1 RNA detection using whole blood versus plasma in antiretroviral-treated individuals.Journal of clinical microbiology · 2025Article
- Soluble CD14 and IL-12p70 on early antiretroviral therapy predict HIV load setpoint after treatment interruption.AIDS (London, England) · 2025Article
- Longitudinal changes in the transcriptionally active and intact HIV reservoir after starting ART during acute infection.Journal of virology · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma viral load (VL) and CD4+ T cell count are widely used as biomarkers of HIV type 1 (HIV-1) replication, pathogenesis, and response to antiretroviral therapy (ART). However, the clinical potential of cell-associated (CA) HIV-1 molecular markers is much less understood. Here, we measured CA HIV-1 RNA and DNA in HIV-infected individuals treated with temporary ART initiated during primary HIV-1 infection. We demonstrate substantial predictive value of CA RNA for (a) the virological and immunological response to early ART, (b) the magnitude and time to viral rebound after discontinuation of early ART, and (c) disease progression in the absence of treatment. Remarkably, when adjusted for CA RNA, plasma VL no longer appeared as an independent predictor of any clinical endpoint in this cohort. The potential of CA RNA as an HIV-1 clinical marker, in particular as a predictive biomarker of virological control after stopping ART, should be explored in the context of HIV-1 curative interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.